Atlas Lithium Corporation (Nasdaq: ATLX) — Q1 2024 Form 10-Q
Period: Three months ended March 31, 2024; balance sheet compared with December 31, 2023. Financial statements are unaudited. Atlas is a Brazil-focused mineral exploration and development company, primarily advancing its Minas Gerais hard-rock lithium project. It had not yet generated material product revenue.
Financial results and position
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $186,707 | $0 in Q1 2023 |
| Cost of revenue | $102,067 | $0 in Q1 2023 |
| Gross result | Statement labels $84,639 as “gross loss”; revenue less cost implies a positive gross result, so the label or amount should be checked. | — |
| Operating expenses | $13.27 million | $4.48 million in Q1 2023 |
| Net loss | $13.18 million; $12.96 million attributable to Atlas shareholders; loss per share $1.29 | $4.47 million; $3.97 million attributable to Atlas shareholders; loss per share $0.60 |
| Cash and cash equivalents | $17.53 million on the balance sheet | $29.55 million at December 31, 2023 |
| Operating cash flow | $(6.10) million | $(3.66) million in Q1 2023 |
| Investing cash flow | $(6.06) million, mainly capital assets and intangible assets | $(1.28) million in Q1 2023 |
| Financing cash flow | $0 | $9.56 million in Q1 2023 |
| Current assets / current liabilities | $17.71 million / $6.43 million | Working capital reported by management: $11.28 million |
| Total liabilities | $35.10 million, including $9.96 million convertible debt and $18.60 million deferred royalty-sale consideration | $34.37 million at December 31, 2023 |
| Total stockholders’ equity | $2.60 million | $9.31 million at December 31, 2023 |
Changes versus Q1 2023 and liquidity
- Net loss increased by $8.72 million. Management attributed the deterioration principally to higher general and administrative costs, increased stock-based compensation, and expanded lithium exploration and drilling.
- Stock-based compensation expense was $6.84 million versus $1.13 million. Exploration expense rose to $3.17 million from $1.03 million; general and administrative expense rose to $3.25 million from $2.32 million.
- Cash declined by $12.02 million during the quarter. Investing cash use increased as the company paid for processing-plant construction; operating cash use also increased. There was no financing cash inflow in Q1 2024, unlike the prior-year quarter.
- Management said cash on hand should cover working capital and capital expenditure needs for at least 12 months, but noted that additional equity or debt financing may be needed and that unavailable or unfavorable financing could require scaling back plans.
- The filing gives inconsistent cash figures: the balance sheet and cash-flow statement report $17.53 million at March 31, while MD&A elsewhere states $17.73 million. The reported working-capital amount is $11.28 million.
Outlook, operations, risks and unusual items
- The company targets Phase I spodumene concentrate production in Q4 2024, with a planned maximum capacity of 150,000 tonnes per year; Phase II is targeted for mid-2025, with intended capacity of 300,000 tonnes per year. These are forward-looking targets, not assured outcomes.
- Estimated total capital expenditure for initial production and ramp-up is $49.5 million. The filing reports $5.28 million of contractual obligations for plant construction and land acquisition, all due within one year.
- Management described plant-module fabrication and trial assembly in South Africa as progressing on schedule. The company continues exploration at the Neves Project and is working with SGS Canada on a maiden resource report; no resource estimate value is provided in this filing.
- On April 4, 2024, after quarter-end, Atlas closed a registered offering of 1,871,250 shares to Mitsui for $30 million gross proceeds. A related offtake agreement covers a 15,000-ton spot quantity and, subject to conditions, up to 60,000 tonnes annually for five years from Phase II. Net proceeds are intended for general corporate purposes, development, working capital and capital expenditures.
- Convertible notes carry 6.5% annual interest and mature in November 2026; holders may convert at $28.225 per share. The debt includes related-party holdings, including $1.99 million owed to Jaeger Investments, an entity controlled by a senior advisor.
- In May 2024, the SEC barred BF Borgers, Atlas’s former auditor, from appearing or practicing before the Commission. Atlas dismissed the firm and engaged Pipara & Co LLP. The filing warns of potential added costs, delays, financing difficulties and effects on market confidence related to the auditor change.
- Principal risks include exploration and resource-estimation uncertainty, permitting and regulatory delays, construction and commissioning execution, access to capital, lithium price and demand changes, mining hazards, and currency exposure from operating primarily in Brazil. Management concluded disclosure controls were effective at a reasonable-assurance level; no material legal proceedings were reported.
Investor verification priorities
- Reconcile the $17.53 million balance-sheet/cash-flow cash figure with the $17.73 million MD&A figure, and confirm the stated working capital.
- Check the income statement’s “gross loss” label against revenue of $186,707 and cost of revenue of $102,067.
- Verify production and construction milestones, the $49.5 million project-cost estimate, remaining funding needs, and whether the stated 12-month liquidity outlook remains achievable.
- Review the terms, conditions and delivery obligations of the Mitsui post-quarter offering and offtake, alongside the company’s other offtake commitments.
- Assess dilution exposure from convertible debt, stock options and awards, and the effect of the auditor transition on future filings and financing access.